echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > It is found that peptide-ibp-cp24 may be a long-acting anti HIV drug

    It is found that peptide-ibp-cp24 may be a long-acting anti HIV drug

    • Last Update: 2019-12-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Recently, scientists from Fudan University and other institutions found that a new engineering peptide-ibp-cp24 may be a long-acting anti HIV drug (, which can be used alone or with a wide range of neutralizing antibodies to treat and prevent HIV-1 infection

    Relevant research is published in the Research Report of international journal PLoS patterns

    In this study, the researchers pointed out that ibp-cp24 can show a long half-life and can potentially carry anti HIV-1 activities widely, even for drug-resistant strains

    Enflutide is the first anti HIV peptide drug approved by FDA (

    However, due to its short half-life and easy to produce drug-resistant HIV strains, its clinical application often has great limitations

    The researchers have developed a new strategy that can extend the half-life of an anti HIV peptide called Cp24 by fusing it into the human immunoglobulin G (IgG) Fc binding peptide (IBP)

      Ibp-cp24 can inhibit broad-spectrum HIV-1 strains, including those resistant to enfluvir; more importantly, its half-life in macaque blood can reach 46.1 hours, which is nearly 26 and 14 times of that of Cp24 and enfluvir; intravenous injection of ibp-cp24 in macaque does not induce significant specific antibody response to ibp-cp24, and does not show significant toxic effect 。 The mice that received ibp-cp24 in advance were also immune from HIV-1 infection, while the mice that received ibp-cp24 and normal human IgG at the same time could significantly reduce the virus content in their blood

    The combination of ibp-cp24 and broad-spectrum HIV neutralizing antibody can show a synergistic anti-HIV-1 effect

    Research shows that this strategy can help reduce the dosage of antibody and peptide, and also reduce the cost of treatment.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.